Co-Diagnostics Stock Moves Higher As Q2 Earnings Top Estimates

  • Co-Diagnostics Inc's CODX Q2 revenue increased 14% Y/Y to $27.4 million, primarily due to Logix Smart COVID-19 Test sales, beating the consensus of $20.77 million.
  • Gross profit increased 37.6% to $24.9 million, with margin expanding to 90.8% from 75.1% in Q2 FY20 due to reduced production costs and improved product mix compared to the prior-year period.
  • Operating income totaled $11.8 million, representing a 19.8% Y/Y decrease due to increased sales and marketing expenses due to increased third-party sales commissions and increased R&D expenses related to the Eikon point of care technology platform.
  • Co-Diagnostics reported EPS of $0.33, down from $0.51 a year ago, surpassing the consensus of $0.22.
  • Cash, cash equivalents, and marketable securities totaled $72.4 million.
  • Guidance: For Q3, Co-Diagnostics expects revenue of $23.0 million - $25.0 million, better than the consensus of $18.12 million.
  • It forecasts EPS of $0.19 - $0.22, compared to the consensus of $0.18.
  • Co-Diagnostics also sees increased development expenses for its Eikon point of care technology platform.
  • Price Action: CODX shares are up 9.93% at $10.63 during the market session on the last check Friday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsLong IdeasNewsGuidanceHealth CareSmall CapMoversTrading IdeasGeneralBriefsDiagnostics
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!